Li et al. found that EPHA5 deficiency promotes Notch1 and PTEN/AKT pathway activation to induce trastuzumab resistance, and is related to the number and performance of breast cancer stem cells, suggesting EPHA5 as a potential biomarker for predicting primary resistance to trastuzumab (20). The gene discussed is AKT1; the disease is breast carcinoma.